@article{ebe6626af89d4222961e42f0a271135c,
title = "Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies",
abstract = "Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.",
author = "Kantarjian, {Hagop M.} and Cortes, {Jorge E.} and Rowe, {Jacob M.} and Razelle Kurzrock",
note = "Funding Information: Dr Kantarjian has received direct support of research from Ortho Biotech Oncology, Schering-Plough, Hoffmann-La Roche Inc, and Novartis. Dr Cortes has received direct support of research from Ortho Biotech Oncology, Schering-Plough, and Bristol-Myers Squibb. This article was supported in part by National Cancer Institute Grant No. 1R21-CA91518A-1 and the Leukemia and Lymphoma Society Grant No. 2057-01. Dr Kurzrock has received significant honoraria from Ortho Biotech Oncology. ",
year = "2002",
month = jul,
doi = "10.1053/shem.2002.35986",
language = "English (US)",
volume = "39",
pages = "36--38",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 2",
}